<DOC>
	<DOCNO>NCT00004889</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness rituximab treat patient Waldenstrom 's macroglobulinemia .</brief_summary>
	<brief_title>Rituximab Treating Patients With Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response , time treatment failure , toxicity patient Waldenstrom 's macroglobulinemia treat rituximab . II . Correlate expression change expression CD20 patient plasma cell B-cells clinical response . OUTLINE : This multicenter study . Patients receive rituximab IV weekly 4 week . Treatment may repeat 2 month later patient stable disease , partial response , complete response . Patients follow every 6 month 2 year . PROJECTED ACCRUAL : A total 12-25 patient accrue study .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Waldenstrom 's Macroglobulinemia require therapy receive 2 prior course therapy ; previously untreated patient slowly progressive WM patient reasonably expect require chemotherapy steroid therapy 90 day CD20 positive tumor cell Presence monoclonal paraprotein Minimum IgM level &gt; 2 time upper limit normal Adequate organ function : ANC &gt; 1000/uL ; PLT &gt; 25000/uL ; serum creatinine &lt; 2.5 ; serum total bilirubin SGOT &lt; 2.5 time upper limit normal 18 year old Life expectancy 6 month great ECOG performance status 02 Men woman reproductive potential must agree use acceptable method birth control treatment 6 month completion treatment Chemotherapy , steroid therapy , radiation therapy within 30 day study entry Patients pregnant Serious comorbid disease Uncontrolled bacterial , fungal , viral infection Active second malignancy Individuals provide inform write consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
</DOC>